Skip to content

Global BioLife

  • Back
PRESS RELEASE

SeD Initial Cancer

Singapore eDevelopment Limited (Stock Code: 40V)’s Biomedical Subsidiary Completes Initial Cancer Research for New Universal Therapeutic Drug Platform

Author adminPosted on 10/01/201806/03/2018

Post navigation

Previous Previous post: Global Biolife PR Linebacker
Next Next post: SeD PR Ebola
  • Back
Global BioLife Proudly powered by WordPress